27
September
2022


Share on networks

The Swiss group Novartis, one of the world leaders in biomedical innovation in cardiology, oncology, immunology, neuroscience, ophthalmology and respiratory areas, will invest 77.4 million euros to expand its production activity in Spain. Of the total investment, 63 million will go to the Barcelona plant.

This centre will increase its production capacity by 150% and will become one of the group’s two antibiotic production hubs for the whole of Spain. This increase in production will generate some 84 new jobs.

INVESTMENT OBJECTIVES

According to Novartis, an investment of close to 100 million euros in R&D&I projects facilitated 287 clinical trials in Spain, involving 7,753 patients.

Marie France Tschudin, global president of the innovative medicines division, defended to the minister and head of the Moncloa economy the need for collaboration between companies and public health systems in order to improve healthcare and thus guarantee patients’ access to the most innovative treatments.

Tschudin stressed that the Swiss company will seek ways of collaborating with the public health system in the field of cardiovascular disease, which has the highest mortality rate.

Share on networks

Related news

Barcelona as an epicenter of science and innovation

News

Barcelona as an epicenter of science and innovation with the creation of the Barcelona Science Innovation District

Cataluña atrae inversiones extranjeras por valor de 880 millones de euros en 2023

News

Catalonia attracts foreign investments worth 880 million euros in 2023

Mountpark expandeix la seva presència a Espanya adquirint terreny per a la construcció d'un centre logístic

News

Mountpark expands its presence in Spain by acquiring land for the construction of a logistics center

Talus Real Estate consolida la seva presència en la logística catalana

News

Talus Real Estate consolidates its presence in Catalan logistics with an acquisition of 47,000 square meters